Separately, analysts at Roth Capital initiated coverage on shares of Nektar Therapeutics in a research note to investors on Thursday, May 24th. They set a “buy” rating on the stock.
Nektar Therapeutics opened at 6.82 on Wednesday. Nektar Therapeutics has a 52-week low of $4.07 and a 52-week high of $8.50. The company’s market cap is $781.6 million.
Nektar Therapeutics last posted its quarterly earnings results on Wednesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.03. The company’s quarterly revenue was up 58.4% on a year-over-year basis. Analysts expect that Nektar Therapeutics will post $-0.32 EPS next quarter.
Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.